Livingstone advises the sale of the Dalberg Klinik AG to the Finnish healthcare provider Mehiläinen OY.

  • nov 2021
  • Healthcare
  • Företagsförvärv
  • Tyskland
  • FÖRETAGSFÖRVÄRV

Livingstone acted as the exclusive M&A-advisor to the founder and single shareholder of the der Dalberg Klinik AG (“Klinik”) Mister Dr. med. Jürgen Vey with its sale to the internationally-active healthcare provider Mehiläinen OY (“Mehiläinen”).

The Dalberg Klinik is a high-quality “Plankrankenhaus” for orthopedic surgery and offers integrated stationary/out-patient healthcare services since the year 2010.

Mehiläinen is a quickly growing, international healthcare company which was founded in Finland already in 1909. Mehiläinen offers a broad spectrum of healthcare services as well as digital healthcare solutions. As part of its internationalization strategy, the company is expanding through the acquisition of the Dalberg Klinik into the German market.

We were looking for a hospital that stood out from the competition and could be used as a Buy & Build platform in Germany. Dalberg Klinik offered us a very attractive infrastructure, a dedicated team and the opportunity to grow. We have big plans for this hospital”, comments Dr. med. Gerald Loos, Managing Director of Mehiläinen Deutschland

The founder and sole shareholder of the Dalberg Klinik, Dr. med. Jürgen Vey, led the hospital for many years as chief physician and CEO and is happy to be working with Mehiläinen on the next chapter of the hospital’s business development.

For us, it is a great honor that such a large and experienced healthcare provider as Mehiläinen has selected us for its first steps on the German market. In my opinion, it is the optimal mix of criteria around a healthy regional center like Fulda and the convincing characteristics of this hospital that have attracted Mehiläinen’s interest in the Dalberg Klinik. The German healthcare market is in urgent need of innovation and Mehiläinen will be an enormous asset to inpatient and outpatient care in our region”, comments Dr. Vey.

The acquisition contract between the Mehiläinen subsidiary Mehiläinen Deutschland GmbH and Dr. Vey was signed the 11th of November 2021 and came into effect the following day. The transaction has no influence on the employees or customers of the Company.

Following the transaction, Dalberg Klinik’s experienced management team will be augmented by Mehiläinen’s Germany managing director, Dr. med. Gerald Loos, who will serve as Dalberg Klinik’s Chief Executive Officer. Dr. med. Jürgen Vey will remain medical director, chief physician and member of the Dalberg Klinik board of directors. The team will continue to grow and develop the company together with the full support of the Mehiläinen Group.

Mehiläinen’s objective is both to expand the range of services offered to different customer groups and to further develop the hospital’s outpatient component with best practices from Finland. Additional digital services will be introduced to complement and improve the availability and scope of healthcare services.

“With the sale of Dalberg Klinik, we were able to successfully sell the second clinic with a focus on orthopedic surgery in the current year 2021, following the sale of Klinikgruppe Dr. Merkle to ATOS and Dalberg Klinik to Mehiläinen, thus demonstrating our strong position in the healthcare market. In addition to positioning ourselves as an active player in the consolidation of the German hospital and MVZ landscape, we are preparing a large number of further transactions in various areas of the exciting healthcare market and expect to conclude further transactions in the near future.”, comments Christian Grandin, Partner at Livingstone.


Dela sidan

Vårt transaktionsteam

Håll dig uppdaterad Missa inga affärer eller analyser